KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesPreferred Dividend PaymentsProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

LifeMD (LFMD) Shares Outstanding (Diluted Average) (2016 - 2025)

LifeMD (LFMD) has disclosed Shares Outstanding (Diluted Average) for 12 consecutive years, with $45.1 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Shares Outstanding (Diluted Average) rose 9.55% year-over-year to $45.1 million, compared with a TTM value of $45.1 million through Dec 2025, up 9.55%, and an annual FY2025 reading of $45.1 million, up 9.55% over the prior year.
  • Shares Outstanding (Diluted Average) was $45.1 million for Q4 2025 at LifeMD, down from $46.2 million in the prior quarter.
  • Across five years, Shares Outstanding (Diluted Average) topped out at $46.2 million in Q3 2025 and bottomed at $24.5 million in Q1 2021.
  • Average Shares Outstanding (Diluted Average) over 5 years is $35.1 million, with a median of $32.8 million recorded in 2023.
  • The sharpest move saw Shares Outstanding (Diluted Average) skyrocketed 128.72% in 2021, then increased 2.68% in 2023.
  • Year by year, Shares Outstanding (Diluted Average) stood at $27.0 million in 2021, then increased by 14.69% to $31.0 million in 2022, then rose by 9.45% to $33.9 million in 2023, then grew by 21.5% to $41.2 million in 2024, then rose by 9.55% to $45.1 million in 2025.
  • Business Quant data shows Shares Outstanding (Diluted Average) for LFMD at $45.1 million in Q4 2025, $46.2 million in Q3 2025, and $44.4 million in Q2 2025.